A hypomorphic Mpi mutation unlocks an in vivo tool for studying global N-glycosylation deficiency
JCI Insight · 2025
DOI: 10.1172/jci.insight.180752 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, 2025. Verfasst von Elisa B Lin und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Genomic and Molecular Pathology, Department of Pathology. Hauptthemen laut MEDLINE: Mannose-6-Phosphate Isomerase, Congenital Disorders of Glycosylation. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIAID NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Glycans are one of the 4 major macromolecules essential for life and are the most abundant family of organic molecules. However, in contrast with DNA and RNA, glycan structures have no template; this results in limited tools to study this challenging macromolecule with a diversity of glycan structures. A central bottleneck in studying glycosylation in vivo is that inhibitors and complete KOs are lethal. In a forward genetic screen, we identified a viable, hypomorphic mutation at a conserved site in mannose phosphate isomerase (Mpi) that causes a multisystemic phenotype affecting RBCs, liver, stomach, intestines, skin, size, fat, and fluid balance in mice. The phenotype could be rescued with mannose. Analyses of glycopeptides in mice with this mutation showed a 500% increase in unoccupied N-glycan sites. This is equivalent to a "glycan knockdown," which would be useful for examining the role of glycans in biology and disease. Therefore, we report an in vivo tool to study global N-glycosylation deficiency with tissue-specific targeting and a rescue mechanism with mannose.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Genomic and Molecular Pathology, Department of Pathology.
- Division of Endocrinology, Department of Internal Medicine.
- Center for Genetics of Host Defense.
- Department of Biochemistry; and.
- Division of Allergy/Immunology, Department of Pediatrics, University of Texas Southwestern (UTSW) Medical Center, Dallas, Texas, USA.
Förderung
- NIDDK NIH HHS
- NIAID NIH HHS
- National Institutes of Health
- Lyda Hill Foundation
Zitieren
APA
Lin, E. B., Meregini, S., Zhang, Z., Roy, A., Argula, T., Mitchell, J. M., Israelsen, W. J., Ludwig, S., Russell, J., Quan, J., Hildebrand, S., Nair-Gill, E., Beutler, B., & SoRelle, J. A. (2025). A hypomorphic Mpi mutation unlocks an in vivo tool for studying global N-glycosylation deficiency. JCI Insight. https://doi.org/10.1172/jci.insight.180752
Vancouver
Lin EB, Meregini S, Zhang Z, Roy A, Argula T, Mitchell JM, et al. A hypomorphic Mpi mutation unlocks an in vivo tool for studying global N-glycosylation deficiency. JCI Insight. 2025. doi:10.1172/jci.insight.180752
BibTeX
@article{Lin2025,
author = {Lin, Elisa B and Meregini, Steve and Zhang, Zhao and Roy, Avishek and Argula, Tandav and Mitchell, James M and Israelsen, William J and Ludwig, Sara and Russell, Jamie and Quan, Jiexia and Hildebrand, Sara and Nair-Gill, Evan and Beutler, Bruce and SoRelle, Jeffrey A},
title = {A hypomorphic Mpi mutation unlocks an in vivo tool for studying global N-glycosylation deficiency},
journal = {JCI Insight},
year = {2025},
doi = {10.1172/jci.insight.180752}
}
EUVIMED